Brokerages forecast that Clorox Co (NYSE:CLX) will announce $1.48 billion in sales for the current quarter, according to Zacks Investment Research. Five analysts have provided estimates for Clorox’s earnings. The highest sales estimate is $1.49 billion and the lowest is $1.47 billion. Clorox reported sales of $1.42 billion during the same quarter last year, which indicates a positive year-over-year growth rate of 4.2%. The business is scheduled to issue its next earnings report on Friday, February 1st.
On average, analysts expect that Clorox will report full-year sales of $6.33 billion for the current fiscal year, with estimates ranging from $6.28 billion to $6.36 billion. For the next financial year, analysts expect that the company will report sales of $6.50 billion, with estimates ranging from $6.45 billion to $6.57 billion. Zacks’ sales calculations are an average based on a survey of sell-side research firms that follow Clorox.
Clorox (NYSE:CLX) last released its quarterly earnings data on Wednesday, October 31st. The company reported $1.62 earnings per share for the quarter, beating the consensus estimate of $1.59 by $0.03. The business had revenue of $1.56 billion for the quarter, compared to analyst estimates of $1.53 billion. Clorox had a return on equity of 102.65% and a net margin of 13.59%. The company’s revenue was up 4.2% compared to the same quarter last year. During the same period in the previous year, the company posted $1.46 EPS.
CLX has been the subject of a number of research analyst reports. Bank of America reiterated a “neutral” rating and issued a $170.00 price target (up from $150.00) on shares of Clorox in a report on Thursday. Zacks Investment Research lowered Clorox from a “hold” rating to a “sell” rating in a research report on Monday. Citigroup lifted their target price on Clorox from $153.00 to $169.00 and gave the stock a “hold” rating in a report on Tuesday, November 20th. BMO Capital Markets lifted their target price on Clorox from $153.00 to $165.00 and gave the stock a “buy” rating in a report on Friday, November 2nd. Finally, Barclays set a $138.00 price target on Clorox and gave the company a “hold” rating in a research note on Thursday, November 1st. Five research analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $144.93.
CLX stock opened at $163.76 on Friday. The company has a current ratio of 1.07, a quick ratio of 0.65 and a debt-to-equity ratio of 3.38. Clorox has a 52-week low of $113.57 and a 52-week high of $167.70. The company has a market cap of $20.89 billion, a price-to-earnings ratio of 26.16, a price-to-earnings-growth ratio of 4.02 and a beta of 0.30.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, February 8th. Shareholders of record on Wednesday, January 23rd will be paid a $0.96 dividend. The ex-dividend date of this dividend is Tuesday, January 22nd. This represents a $3.84 annualized dividend and a yield of 2.34%. Clorox’s dividend payout ratio (DPR) is 61.34%.
In other Clorox news, COO Dawn C. Willoughby sold 54,205 shares of the firm’s stock in a transaction on Tuesday, November 6th. The shares were sold at an average price of $157.39, for a total value of $8,531,324.95. Following the completion of the transaction, the chief operating officer now directly owns 37,044 shares of the company’s stock, valued at approximately $5,830,355.16. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Benno O. Dorer sold 152,449 shares of the firm’s stock in a transaction on Tuesday, December 4th. The shares were sold at an average price of $164.83, for a total transaction of $25,128,168.67. Following the completion of the transaction, the chief executive officer now directly owns 111,735 shares of the company’s stock, valued at $18,417,280.05. The disclosure for this sale can be found here. In the last quarter, insiders sold 239,901 shares of company stock valued at $38,967,571. Company insiders own 1.40% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Berkshire Asset Management LLC PA increased its holdings in Clorox by 17.6% in the 3rd quarter. Berkshire Asset Management LLC PA now owns 3,119 shares of the company’s stock worth $469,000 after acquiring an additional 467 shares in the last quarter. Carillon Tower Advisers Inc. boosted its position in shares of Clorox by 82.8% during the 2nd quarter. Carillon Tower Advisers Inc. now owns 109,150 shares of the company’s stock valued at $14,763,000 after acquiring an additional 49,450 shares during the last quarter. Legacy Advisors LLC acquired a new position in Clorox in the third quarter valued at about $150,000. Victory Capital Management Inc. lifted its position in Clorox by 0.4% in the second quarter. Victory Capital Management Inc. now owns 105,329 shares of the company’s stock valued at $14,246,000 after buying an additional 456 shares during the last quarter. Finally, Homrich & Berg lifted its position in Clorox by 6.5% in the second quarter. Homrich & Berg now owns 9,021 shares of the company’s stock valued at $1,220,000 after buying an additional 552 shares during the last quarter. 77.96% of the stock is owned by institutional investors.
Clorox Company Profile
The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Cleaning, Household, Lifestyle, and International. The company offers laundry additives, including bleach products under the Clorox brand, as well as Clorox 2 stain fighter and color booster; home care products primarily under the Clorox, Formula 409, Liquid-Plumr, Pine-Sol, S.O.S, and Tilex brands; naturally derived products under the Green Works brand; and professional cleaning, disinfecting, and food service products under the Clorox, Dispatch, HealthLink, Clorox Healthcare, Hidden Valley, KC Masterpiece, and Soy Vay brands.
Read More: What is Depreciation?
Get a free copy of the Zacks research report on Clorox (CLX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com